Showing 1701-1710 of 3315 results for "".
- Bio-Tissue Highlights Publication of DREAM Studyhttps://modernod.com/news/bio-tissue-highlights-publication-of-dream-study/2480079/Bio-Tissue highlighted the publication of the Dry Eye Amniotic Membrane (DREAM) study in Clinical Ophthalmology.[1] This retrospective study was conducted at 10 clinical sites in the United States, led by Marguerite McDonald, MD, and Hosam Sheha, MD. It demonstrates that a single applica
- Kiora Pharmaceuticals Receives $1.2 Million in Research Tax Credits to Advance the Treatment of Ophthalmic Diseasehttps://modernod.com/news/kiora-pharmaceuticals-receives-12-million-in-research-tax-credits-to-advance-the-treatment-of-ophthalmic-disease/2481713/Kiora Pharmaceuticals announced its wholly owned subsidiaries have received, in aggregate, $1.2 million related to research tax incentives from the Austrian and Australian governments for research expenditures performed in 2021 and 2022. The funds were received as part of government incentiv
- Beacon Therapeutics Completes Enrollment in Registrational Phase 2/3 VISTA Trial of laru-zova for Patients with XLRPhttps://modernod.com/news/beacon-therapeutics-completes-enrollment-in-registrational-phase-23-vista-trial-of-laru-zova-for-patients-with-xlrp-1/2482875/Beacon Therapeutics announced it has completed enrollment in its registrational phase 2/3 VISTA trial evaluating laru-zova for the treatment of X-linked retinitis pigmentosa (XLRP). The study enrolled eligible male patients aged 12 to 50 across sites in North America, the United Kingdom
- First Patients Enrolled in 4DMT's Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMDhttps://modernod.com/news/first-patients-enrolled-in-4dmts-phase-3-clinical-trial-evaluating-4d-150-in-wet-amd/2482694/4D Molecular Therapeutics (4DMT) announced that the first patients have been enrolled across multiple sites in the 4FRONT-1 phase 3 clinical trial evaluating 4D-150 for the treatment of wet age-related macular degeneration (AMD). "This is a historic moment for 4DMT as we becom
- Nacuity Pharmaceuticals Advances Phase 1/2 Trial Evaluating NPI-002 Intravitreal Implant for the Delay of Cataract Progressionhttps://modernod.com/news/nacuity-pharmaceuticals-advances-phase-12-trial-evaluating-npi-002-intravitreal-implant-for-the-delay-of-cataract-progression/2481719/Nacuity Pharmaceuticals announced that a clinical trial site has been added to its phase 1/2 clinical trial evaluating NPI-002, a proprietary antioxidant molecule delivered via a sustained release intravitreal implant, for the delay of cataract progression in patients undergoing vitrectomy.
- Lumibird Medical Renames its Polish Subsidiary to Lumibird Medical Polskahttps://modernod.com/news/lumibird-medical-renames-its-polish-subsidiary-to-lumibird-medical-polska/2481613/Lumibird Medical Group has renamed its Polish subsidiary, Quantel Medical Polska, to Lumibird Medical Polska. After 5 years of existence, the Polish subsidiary, with a constant double-digit growth since its creation, has moved to a larger site in Warsaw. “
- Eye Love Rock ‘N Roll Event Headlining Holland Foundation Fundraiser at ASCRShttps://modernod.com/news/eye-love-rock-n-roll-event-headlining-holland-foundation-fundraiser-at-ascrs/2481454/A band of ophthalmologists and industry professionals will perform during the Holland Foundation of Site Restoration’s fundraiser, “Eye Love Rock ‘N Roll,” during the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in San Diego. Th
- Luminopia One Demonstrates Safety and Efficacy in Phase 3 Pivotal Trial for Amblyopiahttps://modernod.com/news/luminopia-one-demonstrates-safety-and-efficacy-in-phase-3-pivotal-trial/2480274/Luminopia announced the publication of positive phase 3 pivotal data of its investigational treatment for amblyopia—Luminopia One. Published in Ophthalmology, the study was conducted at 21 academic and community sites in the U.S., in which childre
- Zeiss Opens New High-Tech Center in San Francisco Bay Areahttps://modernod.com/news/zeiss-opens-new-high-tech-center-in-san-francisco-bay-area/2479038/Zeiss has completed construction of its new R&D, production, sales and customer service site in the San Francisco Bay Area. Bringing together hundreds of Zeiss employees and key functions under one roof, represents a major milestone in the company’s international innovation and growth
- Clearside Biomedical Announces First Patients Enrolled in Phase 1/2a Clinical Trial of CLS-AX for the Treatment of Wet AMDhttps://modernod.com/news/clearside-biomedical-announces-first-patients-enrolled-in-phase-1-2a-clinical-trial-of-cls-ax-for-the-treatment-of-wet-amd/2478744/Clearside Biomedical announced that the first patients have been enrolled in its phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) in patients with wet age-related macular degeneration (AMD). Clinical sites, all based in the United States, are activated and curr